Ortho-McNeil-Janssen Pharma signs pact with Koch Institute for Integrative Cancer Research at MIT

Ortho-McNeil-Janssen Pharmaceuticals, Inc.(OMJPI) announced the signing of a five-year collaboration agreement with the David H Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). Called TRANSCEND, the collaboration agreement will foster oncology research and technology development in the areas of cancer diagnostics, cancer biology pre-malignancies …